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Gender-biased vessel growth
A man’s male hormones may ward off heart damage by helping vessels around the heart regenerate, 
suggest Sieveking and colleagues.
Although studies have shown that estrogen helps regenerate blood vessels, both in the uterus 
after menstruation and around the heart after wear and tear, little is known about whether or not 
men make up for a lack of the female hormone. Some researchers have theorized that this disparity 
accounts for why men tend to suffer worse heart attacks more often and earlier in life than 
women. However, Sieveking and colleagues find that this trend may be due to a drop in androgens, 
a collective term for male hormones, as men age.
Angiogenic activities like cell migration ensued after the authors treated human cells derived 
from the umbilical cord of a male fetus with the androgen DHT. Meanwhile, female cells failed 
to respond to the androgen, unless they were supplied with extra androgen receptors. In this case, 
angiogenic activities increased slightly, indicating that hormone sensitivity accounts for some of 
the gender difference.
Castrated mice produced fewer androgens and fared poorly after the researchers inflicted vessel 
damage intended to resemble injuries that occur during a heart attack or a stroke. And treating the 
castrated mice with DHT hastened their recovery. Therefore, the authors suggest that androgen 
replacement therapy might one day be used to treat men at risk for heart disease. The therapy currently 
receives attention for possibly inducing other rejuvenating benefits, such as increased energy and 
muscle mass. However, it’s been approached with caution as androgens have been shown to assist in 
tumor growth in prostate cancer—perhaps by stimulating cancer-promoting angiogenesis.
Androgen treatments correlated with spikes in the growth factor VEGF, and blocking VEGF 
interrupted androgen-induced angiogenesis. However, androgens may also modulate angiogenesis 
by mobilizing progenitor cells known to be critical for vessel repair; the authors found that castrated 
mice had fewer progenitor cells in circulation after injury than those with their organs intact.
Accelerated aging
Mutations underlying a rare disorder in which children rapidly age disrupt mitochondrial DNA 
repair, show Kamenisch and colleagues. Faulty repair leads to an accumulation of mutations in 
mitochondrial DNA, a molecular hallmark of growing old.
Recent studies have connected the excess of mitochondrial gene mutations to signs of aging, 
including hair loss, bone loss, and the loss of subcutaneous fat. The early aging disorder, Cockayne 
syndrome (CS), is also marked by fat loss, along with sensitivity to UV radiation, which reflects 
faulty DNA repair. CS patients bear defects in the nucleotide excision repair (NER) pathway, 
which until now was only known to act on nuclear DNA. Here, Kamenisch and colleagues 
discover that NER proteins rush into the mitochondria during times of oxidative stress.
When the defective NER proteins that characterize CS—CSA and CSB—entered mitochondria 
after irradiation, errors accumulated rapidly during mitochondrial DNA replication in cultured 
cells from CS patients. CSA and CSB interacted with mitochondrial proteins in the base excision 
DNA repair pathway, which normally removes oxidative damage. The authors speculate that 
interactions between NER proteins and base excision proteins form a reparative complex; 
however, the details of that proposed network remain elusive. How CSA and CSB enter the 
mitochondria in times of stress remains to be investigated as well.
A buildup of mitochondrial gene mutations could be responsible for the subcutaneous fat loss 
characteristic of CS, suggest the authors. Indeed, the subcutaneous fat of adult, irradiated mice 
lacking CSA and CSB was teeming with mitochondrial DNA mutations. And fat cells with many 
mutations often died, reducing the overall number of fat cells in the mice.
Androgen treatment repaired (arrows) 
damaged vessels in castrated mice.
CSB (red) moved into mitochondria 
(blue) after oxidative stress.
Antibodies attack IL-17
Two new studies suggest why patients with the autoimmune disorder APS-I are susceptible to 
chronic yeast infections. According to Puel et al. and Kisand et al., APS-I patients produce 
autoantibodies against microbe-fighting cytokines—making this disorder one of a small handful 
of diseases enhanced by antibodies that target cytokines.
The yeast infection, known as chronic mucocutaneous candidiasis, usually develops before other 
symptoms of APS-I. The infection is perplexing given that many autoimmune disorders are 
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Cancers converge at 2-HG
Several mutations associated with acute myelogenous leukemia (AML) lead to the same metabolic 
change, report Gross and colleagues.
Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) occur in about 80% of secondary 
brain cancer tumors, and in nearly a tenth of AML tumors. Normally, IDH1 catalyzes a critical 
step in glucose metabolism in the cytoplasm—the conversion of isocitrate into  -ketoglutarate. 
However, when the amino acid arginine at position 132 of IDH1 mutates, the enzyme acquires 
new powers. It reduces  -ketoglutarate into R(-)-2-hydroxyglutarate (2-HG), an “onco-
metabolite” recently linked to the development of brain cancer and here, to AML.
The authors find that AML patients with IDH1 mutations at position 132 harbor high serum levels 
of 2-HG. However, the mutations from AML patients often differed from those of brain cancer 
patients by an amino acid; instead of primarily switching to histidine, arginine had frequently changed 
to cysteine. And the cysteine variant showed a higher affinity for  -ketoglutarate, which led to more 
2-HG. The team uncovered an additional mutation in IDH2, IDH1’s counterpart that acts in the 
peroxisome. Likewise, this mutant IDH2 enzyme converted  -ketoglutarate into 2-HG.
Although the effect of 2-HG on tumor growth is unknown, the authors speculate that it may 
promote tumor progression by elevating reactive oxidative species or by altering cell metabolism 
by inhibiting key enzymes. In any case, because these ID1H mutations appear to be unique to 
cancer, they provide promising targets for drugs and biomarkers of the disease.
APS-I patients harbored autoantibodies 
against IFN-, IL-17A, IL-17F, and 
IL-22.
AML patients with the IDH1 R132 
mutation harbored high serum levels 
of 2-HG.
IL-17F, and IL-22 that fight microbial pathogens at mucosal surfaces. On the contrary, here the 
teams suggest that APS-I patients have diminished Th17 activity due to autoantibodies against these 
signature cytokines. Kisand et al. found that cultured progenitor cells from APS-I patients produced 
less IL-17F and IL-22 in response to yeast antigens or polyclonal stimuli. And although some cells 
made less IL-17A as well, cytokine levels varied overall, likely reflecting variation in genetic, 
environmental, or clinical backgrounds.
The paucity of cytokines correlated with the presence of autoantibodies against IL-17A, IL-17F, 
and IL-22. These autoantibodies blocked or neutralized the cytokines but, according to Kisand 
et al., did not obstruct Th17 cell differentiation. Other inflammatory cytokines were unaffected, 
with the exception of interferon (IFN)- , which is known to be blocked by autoantibodies in 
APS-I patients. However, APS-I patients do not appear prone to recurrent viral infections despite 
neutralization of this antiviral cytokine—perhaps because other IFNs compensate.
How these autoantibodies arise remains a mystery. Infection was not the trigger, because 
APS-I patients without candidiasis produced them as well. The authors suggest that their origin 
may be due to mutations in the gene underlying APS-I, which disrupt the autoimmune regulator 
AIRE. AIRE normally prevents autoreactive T cells from leaving the thymus, but a direct 
connection between the AIRE disruption and anti-cytokine antibodies remains to be seen.
Interferon crossfire
Interferons (IFNs) establish a pecking order in a study by Rayamajhi and colleagues. When type I 
IFNs muffled type II during bacterial invasion, the bacteria won.
Although the protective type II cytokine, IFN- , was expressed after bacteria invaded, infected 
cells weren’t listening. Listeria-infected macrophages up-regulated the type I IFNs, IFN-  and - , 
which down-regulated IFN-  receptors on the cell surface and thus stifled IFN-  signals. Without 
IFN-    receptors, mice resisted Listeria. They expressed IFN- –dependent genes, indicating 
that IFN-  had made contact with its receptors.
In demonstrating that IFN-    mutes IFN- , this team presents a new solution for a long-standing 
conundrum. Namely, why mice deficient in virus-fighting type I IFNs are protected from pathogenic 
bacteria like Listeria monocytogenes and Mycobacterium tuberculosis. Earlier studies postulated that IFN-    
hinder bacterial clearance by triggering the immune-suppressing cytokine IL-10. If this were true, one 
might predict an increase in IFN-  in the absence of IFN-    signals because IL-10 stifles IFN- . 
However, the authors found that with or without IFN-    receptors, mice produced IFN-  after 
infection. The problem was instead that IFN-  messages failed to send with IFN-    receptors intact.
Interferon cross talk may explain why IFN-  treatments work for many multiple sclerosis 
patients. Perhaps, speculate the authors, IFN-  intercepts inflammatory signals from IFN-  by 
dampening expression of its receptors.
IFN- down-regulated IFN- 
receptors on the surface of infected 
macrophages.